SCWorx Receives Nasdaq Hearings Panel Decision Granting Continued Listing

SCWorx Corp., a provider of data normalization and supply chain solutions for the healthcare industry, has received a decision from the Nasdaq Hearings Panel granting its request to continue listing on The Nasdaq Stock Market. However, this approval is subject to the company satisfying certain compliance conditions.

The decision comes after trading in SCWorx’s common stock was suspended on April 14, 2026 due to the company’s failure to meet the requirements of Nasdaq Listing Rule 5550(a)(2). This rule mandates that companies maintain a minimum market value of publicly held shares and a certain level of public float.

The conditions set by the Nasdaq Hearings Panel require SCWorx to demonstrate compliance with these listing rules. The company must now work towards meeting these requirements within a specified timeframe, details of which have not been disclosed.

SCWorx’s management team has expressed relief at this development, stating that it is committed to regaining compliance and continuing its listing on the Nasdaq Stock Market. The company’s shareholders can expect updates on its progress in the coming weeks and months.

Market analysts have noted that SCWorx’s continued listing will be beneficial for investors seeking exposure to the healthcare sector. As the company moves forward, it is likely to remain under close scrutiny from market watchers, who will be monitoring its progress towards compliance with Nasdaq’s listing rules.

Source: original report.